Profil
Nicole Keith is currently working as an Investor Relations Contact at Juno Therapeutics, Inc. since 2015.
She is also currently working as an Investor Relations & Media professional at Sana Biotechnology, Inc. Additionally, Ms. Keith previously worked as the Head-Investor Relations at Onyx Pharmaceuticals, Inc. from 2012 to 2013.
Aktive Positionen von Nicole Keith
| Unternehmen | Position | Beginn |
|---|---|---|
| JUNO THERAPEUTICS INC | Investor Relations Contact | 01.07.2015 |
| SANA BIOTECHNOLOGY, INC. | Director/Board Member | - |
Ehemalige bekannte Positionen von Nicole Keith
| Unternehmen | Position | Ende |
|---|---|---|
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Public Communications Contact | 01.12.2013 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SANA BIOTECHNOLOGY, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
